Ocular Inflammatory Disease Center, Jules Stein Eye Institute and the Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Am J Ophthalmol. 2010 Feb;149(2):214-220.e3. doi: 10.1016/j.ajo.2009.08.030. Epub 2009 Nov 11.
To describe the characteristics and course of late varicella-zoster virus (VZV) dendriform keratitis in patients with histories of herpes zoster ophthalmicus (HZO); to describe responses of corneal lesions to antiviral treatment; and to investigate risk factors for recurrence.
Retrospective case series.
Included were patients known to have 1 or more episodes of dendriform lesions beginning at least 2 weeks after HZO in 2 academic practices. Epithelial lesions were evaluated for the presence of VZV DNA by a polymerase chain reaction assay. Demographic, medical, and ophthalmic data were collected for each episode. Responses to treatment with antiviral medications were evaluated. Cumulative risk of recurrence was determined using Kaplan-Meier analysis; potential risk factors for recurrence (age, systemic disease, lesion characteristics, corticosteroids) were evaluated using univariate Cox proportional hazard models.
We identified 20 patients (14 women; median age, 65 years) who met inclusion criteria. Dendriform lesions were pleomorphic with thickened, opaque epithelium. Seven patients had systemic diseases characterized by altered immune function. VZV DNA was identified in 15 of 16 cases tested, and all lesions responded to antiviral therapy. The 1-year incidence of first recurrence was 95.8 lesions per 100 person-years of follow-up. Patients had multiple recurrences, but risk of recurrence appeared to decrease over time. No statistically significant risk factors for recurrence were identified.
Late dendriform lesions associated with HZO are foci of productive VZV infection. Lesions can be treated effectively with topical or systemic antiviral agents. Patients can have multiple recurrences of dendriform lesions despite treatment.
描述有带状疱疹病史患者中晚期水痘带状疱疹病毒(VZV)树突状角膜炎的特征和病程;描述角膜病变对抗病毒治疗的反应;并探讨复发的危险因素。
回顾性病例系列。
纳入标准为在 2 个学术实践中,至少在带状疱疹后 2 周出现 1 次或多次树突状病变的患者。通过聚合酶链反应检测上皮病变中是否存在 VZV DNA。收集每个发作的人口统计学、医学和眼科数据。评估抗病毒药物治疗的反应。使用 Kaplan-Meier 分析确定复发的累积风险;使用单变量 Cox 比例风险模型评估复发的潜在危险因素(年龄、系统性疾病、病变特征、皮质类固醇)。
我们确定了符合纳入标准的 20 名患者(14 名女性;中位年龄 65 岁)。树突状病变形态多样,上皮增厚、混浊。7 名患者患有以免疫功能改变为特征的系统性疾病。在 16 例检测的病例中,有 15 例检测到 VZV DNA,所有病变均对抗病毒治疗有反应。第 1 年的首次复发率为每 100 人年随访 95.8 个病变。患者有多次复发,但复发风险似乎随时间降低。未发现复发的统计学显著危险因素。
与带状疱疹相关的晚期树突状病变是 VZV 复制的焦点。病变可以通过局部或全身抗病毒药物有效治疗。尽管进行了治疗,患者仍可能多次出现树突状病变复发。